Education
About Us
Working with TipRanks
Follow Us
Elite Pharmaceuticals (ELTP)
OTHER OTC:ELTP
Earnings Data
Report Date
Feb 16, 2026TBA (Confirmed)
Period Ending
2026 (Q3)Consensus EPS Forecast
―Last Year’s EPS
-0.01Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
Elite Pharmaceuticals reported strong revenue growth and improved operating profits, driven by increased market share and a robust product pipeline. However, increased competition has affected profit margins, and higher administrative costs have been noted. The company's balance sheet remains strong, but market dynamics could present challenges.Company Guidance
Record Revenue Growth
Total revenues for the quarter were $36.3 million, a 92% increase compared to $18.8 million for the September 2024 quarter. Revenues for the first six months of fiscal 2026 were $76.5 million, a 103% increase compared to $37.7 million for the same period last year.
Strong Operating Profit and Cash Flow
Operating profits for the quarter were $8.2 million, a 136% increase from $4.7 million in the September 2024 quarter. Operating cash flow for the six months was $19.9 million, a 333% increase compared to $4.6 million for the same period last year.
Increased Market Share for Key Products
Elite maintained an 8% market share for Lisdexamfetamine and a 19% market share for amphetamine IR, according to internal data. The company also commands a 30% market share for phendimetrazine.
Strengthened Balance Sheet
Working capital increased by 63% to $75 million, with current assets rising from $58 million to $86 million and current liabilities decreasing from $11.8 million to $10.7 million.
Expansion and Pipeline Progress
Elite plans to launch Ropinirole ER in Q2 and has a pending review for Oxy ER by the FDA. The company also plans to file an ANDA for an anticoagulant generic in Q1 2026.
ELTP Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ELTP Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 14, 2025 | $0.68 | $0.58 | -14.71% |
Aug 14, 2025 | $0.53 | $0.53 | 0.00% |
Jun 30, 2025 | $0.73 | $0.67 | -8.22% |
Feb 13, 2025 | $0.55 | $0.53 | -3.64% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Elite Pharmaceuticals (ELTP) report earnings?
Elite Pharmaceuticals (ELTP) is schdueled to report earning on Feb 16, 2026, TBA (Confirmed).
What is Elite Pharmaceuticals (ELTP) earnings time?
Elite Pharmaceuticals (ELTP) earnings time is at Feb 16, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ELTP EPS forecast?
Currently, no data Available